Zai Lab Yönetim

Yönetim kriter kontrolleri 3/4

Zai Lab CEO'su Samantha Du, Jan2014 tarihinde atandı, in görev süresi 10.83 yıldır. in toplam yıllık tazminatı $ 12.04M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.2% maaş ve 92.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.01% ine doğrudan sahiptir ve bu hisseler HK$ 217.33M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 6.2 yıldır.

Anahtar bilgiler

Samantha Du

İcra Kurulu Başkanı

US$12.0m

Toplam tazminat

CEO maaş yüzdesi	7.2%
CEO görev süresi	10.8yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	6.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Samantha Du'un ücretlendirmesi Zai Lab'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$271m
Jun 30 2024	n/a	n/a	-US$298m
Mar 31 2024	n/a	n/a	-US$339m
Dec 31 2023	US$12m	US$869k	-US$335m
Sep 30 2023	n/a	n/a	-US$301m
Jun 30 2023	n/a	n/a	-US$393m
Mar 31 2023	n/a	n/a	-US$410m
Dec 31 2022	US$20m	US$830k	-US$443m
Sep 30 2022	n/a	n/a	-US$593m
Jun 30 2022	n/a	n/a	-US$529m
Mar 31 2022	n/a	n/a	-US$554m
Dec 31 2021	US$15m	US$774k	-US$704m
Sep 30 2021	n/a	n/a	-US$569m
Jun 30 2021	n/a	n/a	-US$537m
Mar 31 2021	n/a	n/a	-US$454m
Dec 31 2020	US$9m	US$689k	-US$269m
Sep 30 2020	n/a	n/a	-US$239m
Jun 30 2020	n/a	n/a	-US$240m
Mar 31 2020	n/a	n/a	-US$201m
Dec 31 2019	US$9m	US$656k	-US$195m
Sep 30 2019	n/a	n/a	-US$212m
Jun 30 2019	n/a	n/a	-US$181m
Mar 31 2019	n/a	n/a	-US$160m
Dec 31 2018	US$6m	US$638k	-US$139m

Tazminat ve Piyasa: Samantha 'nin toplam tazminatı ($USD 12.04M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 515.61K ).

Tazminat ve Kazançlar: Samantha 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Samantha Du (58 yo)

10.8yrs

Görev süresi

US$12,042,285

Tazminat

Dr. Ying Du, Ph D., also known as Samantha, serves as Founding Managing Director at Quan Capital. She served as Venture Partner at Sequoia Capital China.Dr. Du serves as an adjunct professor at Fudan Univ...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ying Du	Founder	10.8yrs	US$12.04m	1.01% HK$ 217.3m
Joshua L. Smiley	President & COO	2.3yrs	US$5.55m	0.044% HK$ 9.5m
Rafael G. Amado	President and Head of Global Research & Development	1.8yrs	US$4.87m	0.021% HK$ 4.5m
Yajing Chen	Chief Financial Officer	1.3yrs	US$2.01m	0.016% HK$ 3.4m
Peter Huang	Chief Scientific Officer	2yrs	Veri yok	Veri yok
Christine Chiou	Senior VP & Head of Investor Relations	1.5yrs	Veri yok	Veri yok
Frazor Titus Edmondson	Chief Legal Officer & Joint Corporate Secretary	4.3yrs	US$5.63m	0.029% HK$ 6.3m
Ning Xu	Executive VP & Head of Clinical Operations	10.8yrs	Veri yok	Veri yok
Jonathan J. Wang	Chief Business Officer	10.8yrs	Veri yok	Veri yok
James Yan	Chief Operating Officer of R&D	9.8yrs	Veri yok	Veri yok
Tong Zhu	Chief Commercial Officer of Greater China	less than a year	Veri yok	Veri yok
Robert Brown	Chief Medical Officer of Oncology	1.2yrs	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 9688 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ying Du	Founder	10.8yrs	US$12.04m	1.01% HK$ 217.3m
Leon Moulder	Independent Director	4.8yrs	US$574.35k	0.041% HK$ 8.9m
Peter Karl Wirth	Independent Director	7.8yrs	US$576.15k	0.37% HK$ 79.1m
John David Diekman	Lead Independent Director	7.8yrs	US$608.44k	0.069% HK$ 14.8m
Scott William Morrison	Independent Director	3.1yrs	US$570.77k	0.053% HK$ 11.5m
William David Lis	Independent Director	6.1yrs	US$567.03k	0.054% HK$ 11.6m
Michel Vounatsos	Independent Director	1.8yrs	US$821.25k	0.019% HK$ 4.0m
Richard Brian Gaynor	Independent Director	3yrs	US$564.98k	0.026% HK$ 5.5m
Kai-Xian Chen	Independent Director	6.3yrs	US$557.48k	0.048% HK$ 10.3m
Wing-Yu Leung	Independent Director	10.8yrs	Veri yok	Veri yok

6.2yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 9688 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.2 yıldır).

Zai Lab Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer

Recent updates

Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million.

Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million.

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310

Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024

Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib

Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration

Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer

Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer

Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022

China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited

Zai Lab Limited Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Zai Lab Limited, Annual General Meeting, Jun 22, 2022

Zai Lab Limited to Report Q1, 2022 Results on May 10, 2022

Zai Lab Limited Announces Resignation of Tao Fu, Chief Strategy Officer

Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 02, 2022

Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 01, 2022

Zai Lab Limited Announces Treatment of First Patient in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer

Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA

Zai Lab Limited Announces China NMPA's Approval for NUZYRA® as A Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Zai Lab Announces Inclusion of Zejula® (Niraparib) in China's National Reimbursement Drug List for First-Line Ovarian Cancer

Zai Lab Limited Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib)

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

Zai Lab Announces First Patient Treated in Greater China in Metis Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited Announces Recent Product Highlights and Anticipated Milestones

Zai Lab Limited Appoints Ann Beasley as Chief Compliance Officer

Zai Lab Expects to Receive Approval for and Launch QINLOCK and NUZYRA in China

Zai Lab Limited to Report Fiscal Year 2020 Results on Mar 01, 2021

Turning Point and Zai Lab Broaden Announces Collaboration

Zai Lab Limited Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Alan Sandler as President, Head of Global Development, Oncology

Zai Lab Limited Announces Dosing of First Patient in China in the Global Pod1um-101 Study Evaluating Retifanlimab in Patients with Previously Treated, Microsatellite Instability-High Endometrial Cancer

Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC

Zai Lab Limited has completed a Follow-on Equity Offering in the amount of HKD 5.936996 billion.